Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial has found.
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care.
It also slashed the risk of the disease returning in another part of the body, the study suggests.
Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box.
Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers.
The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients.
Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only.
Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer.
By blocking this protein, the treatment helps the immune system fight cancer more effectively.
The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body.
The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care.
After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab.
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades.
'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas.
'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.'
Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'.
'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
an hour ago
- Scottish Sun
Exercise boosts cancer recovery and slashes risk of death or relapse by a third, major study finds
'BETTER THAN A DRUG' Exercise boosts cancer recovery and slashes risk of death or relapse by a third, major study finds EXERCISE is 'better than a drug' at stopping cancer coming back, a landmark trial suggests. Top doctors say recovering patients should be prescribed personal trainers to boost survival. Advertisement 1 People only needed to walk for three to four hours per week to slash their risk of dying (stock image) Credit: Alamy A Cancer Research UK study showed it could slash bowel cancer patients' risk of death or relapse. Following an exercise programme after treatment reduced their risk of dying within eight years by 37 per cent. And it reduced the chance of a patient's cancer growing back within five years by 28 per cent. Physical activity also appeared to cut the risk for breast and prostate cancers, the two most common types. Advertisement 'Drugs are approved for less' Dr Julie Gralow, president of the American Society of Clinical Oncology, said: 'This is the same magnitude of benefit as many drugs. 'Drugs get approved for less than that and they're expensive and toxic, so I would say it's better than a drug.' Dr Pamela Kunz, of Yale University in the US, said prescribing it was a 'no-brainer'. The world-first trial involved 889 people from Canada and Australia who had received surgery and chemotherapy for colon cancer, the most common form of bowel cancer. Advertisement It affects around 32,000 people per year in the UK and develops in the large intestine. Half of the participants were given basic exercise advice and the other half were assigned personal trainers and given tailored exercise programmes for three years. Sun Health Explainer: Bowel Cancer The plan added the equivalent of three to four hours of walking on top of patients' normal daily activity. At the end of the 15-year trial, people in the personal trainer group were significantly less likely to have relapsed or died. Advertisement Study author Dr Christopher Booth, from Queen's University in Kingston, Canada, said: 'These results are clear: an exercise program that includes a personal trainer will reduce the risk of recurrent or new cancer, make you feel better and help you live longer. 'Most patients chose a walking program and could reach their targets by going for a walk of 45 to 60 minutes three to four times per week. 'The benefit was substantial and in some cases exceeded the benefit of many of our very good medical therapies. 'This sets a new standard of care for colon cancer.' Advertisement If you start exercising after you get through your treatment you still get the benefits – it's not too late Dr Julie Gralow He said that one life was saved for every 14 patients who enlisted in the exercise programme. It cost an estimated £2,500 per patient over three years and the Canadian government is now looking at including it in hospital care. Dr Gralow added: 'If you start exercising after you get through your treatment you absolutely still get the benefits – it's not too late. 'Three decades ago it was still the era of doctors being gentle and saying don't overdo it, but we've reversed that and had a major shift in understanding the importance of physical activity. Advertisement 'We should be doing all we can to help patients be active.'
Leader Live
2 hours ago
- Leader Live
New drug can help stop certain breast cancer tumours early, trial shows
A trial called Serena-6 shows that camizestrant stops cancer cells from using hormones to grow, which helps patients stay well longer and delays the need for chemotherapy. It is the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients, scientists say. The study looked at patients who had hormone-positive, HER2-negative breast cancer, which is about 70% of cases. Results showed patients given camizestrant reduced their chances of cancer progression by 56%, compared with just standard therapies. Doctors used a simple blood test to spot changes in the cancer's DNA that show whether current treatments might soon stop working. When they found these signs, some patients were given camizestrant, while others stayed on their usual treatment. Those on camizestrant had their cancer stay the same and not get worse for much longer, 16 months on average, compared with about nine months for the others. The drug was safe for most patients but 1% stopped taking it because of side effects. More than 3,000 patients from 23 countries took part in the study, which was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research in London. Co-principal investigator Professor Nick Turner, group leader in molecular oncology at The Institute of Cancer Research, London, said the drug is 'a pivotal moment in breast cancer care'. Professor Kristian Helin, chief executive of The Institute of Cancer Research said: 'The results of the Serena-6 trial represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine.' About 55,000 women are diagnosed with breast cancer in the UK every year and 11,500 will die from the disease, The Institute of Cancer Research said. The Serena-6 trial results were to be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on Sunday. Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
The Sun
2 hours ago
- The Sun
Three-drug treatment combo ‘holds back aggressive breast cancer for a year'
A NEW triple threat drug combination could hold aggressive breast cancer at bay for an extra year, a trial found. Adding the medicine inavolisib to an already used pair of drugs delayed the need for chemotherapy by almost two years. 1 It prevented tumours from growing for an average of 17 months, compared to seven months in patients using the standard drug pairing palbociclib and fulvestrant. An estimated 1,000 British women per year could benefit. The combo works for women with a specific breast cancer type called HR+ HER2- with a PIK3CA mutation, which accounts for about three in 10 cases. Professor Kristian Helin, chief of The Institute of Cancer Research in London, said: 'We need to tackle treatment resistance head-on to continue improving survival rates. 'This triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer.' The trial included 325 patients with aggressive and advanced breast cancer from 28 countries. Cancers shrank in two thirds of people receiving the triple drug combination, compared to 28 per cent of those on standard treatment. New go-to option for docs Study author Professor Nicholas Turner, of the Royal Marsden NHS hospital in London, said: 'This therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing chemotherapy which is something that patients really fear and want to delay for as long as possible.' 'These results give us confidence that this treatment could become the new go-to option.' The study was presented at the conference of the American Society of Clinical Oncology. What are the signs of breast cancer? BREAST cancer is the most common type of cancer in the UK. The majority of women who get it are over 50, but younger women and, in rare cases, men can also get breast cancer. If it's treated early enough, breast cancer can be prevented from spreading to other parts of the body. Breast cancer can have a number of symptoms, but the first noticeable symptom is usually a lump or area of thickened breast tissue. Most breast lumps aren't cancerous, but it's always best to have them checked by your doctor. You should also speak to your GP if you notice any of the following: a change in the size or shape of one or both breasts discharge from either of your nipples (which may be streaked with blood) a lump or swelling in either of your armpits dimpling on the skin of your breasts a rash on or around your nipple a change in the appearance of your nipple, such as becoming sunken into your breast Source: NHS
